Previous 10 | Next 10 |
BioMarin Pharmaceutical press release ( NASDAQ: BMRN ): Q3 GAAP EPS of -$0.04 misses by $0.03 . Revenue of $505.3M (+23.6% Y/Y) misses by $10.56M . For FY2022, the company expects $2.06B to $2.16B vs. consensus of $2.12B and Non-GAAP net income in the range of ...
BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®) PR Newswire VOXZOGO ® $48 Million Contribution in the Quarter Results in BioMarin Raising Full-year 2022 VOXZOGO Net Product Revenue Guidance to Be...
Summary The standard of care treatments for PKU have safety issues and/or limited efficacy. Recent data showed meaningful efficacy for SYNB1934 in PKU and the company will proceed to phase 3 testing. PTC Therapeutics, a competitor has a phase 3 study underway in PKU. PKU i...
Summary Results from the pivotal VITAL study, using EB-101 for the treatment of patients with RDEB are expected to be released before the end of 2022. Should EB-101 be approved by FDA for RDEB, it would give company a Priority Review Voucher, which could be sold for around $100 mi...
Summary Pharmaceuticals and biotechnology have the best value and quality scores. Healthcare providers look undervalued relative to 11-year averages. Other healthcare industries don’t look attractive. Focus on a biotech ETF: GNOM (and why I don’t like it). ...
The US FDA has accepted the Biologics License Application from BioMarin Pharmaceutical ( NASDAQ: BMRN ) for its hemophilia A gene therapy candidate valoctocogene roxaparvovec. The FDA action date is March 31, 2023. The application is supported by two-year outcomes ...
FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A PR Newswire If Approved, Would Be 1st Gene Therapy in U.S. for Treatment of Severe Hemophilia A PDUFA Target Action Da...
BioMarin Pharmaceutical ( NASDAQ: BMRN ) notifies its decision to redesign the organization to better focus investments that advance its R&D pipeline, maximize recent commercial launch success, prepare for a potential launch of ROCTAVIAN in the U.S., and drive core infrast...
BioMarin Simplifies Organizational Structure to Increase Efficiency PR Newswire SAN RAFAEL, Calif. , Oct. 6, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced its decision to redesign the organization to better focus investme...
BioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , Oct. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Ja...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...